Chronic Myeloid Leukemia

Common Name(s)

Chronic Myeloid Leukemia

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Chronic Myeloid Leukemia" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Chronic Myeloid Leukemia" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Chronic Myeloid Leukemia" returned 1109 free, full-text research articles on human participants. First 3 results:

Rapid oral allopurinol desensitization in a patient with chronic myeloid leukemia.
 

Author(s): Ori Toker, Ariella Tvito, Jacob M Rowe, Jacob Ashkenazi, Chezi Ganzel, Yuval Tal, Meir Shalit

Journal: Isr. Med. Assoc. J.. 2014 Jul;16(7):461-2.

 

Last Updated: 29 Aug 2014

Go To URL
Granulocyte-macrophage colony stimulating factor (GM-CSF) enhances the clinical responses to interferon-α (IFN) in newly diagnosed chronic myeloid leukemia (CML).
 

Author(s): Joshua F Zeidner, Douglas E Gladstone, Marianna Zahurak, William H Matsui, Christopher Gocke, Richard J Jones, B Douglas Smith

Journal: Leuk. Res.. 2014 Aug;38(8):886-90.

 

The majority of chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs) remain with residual disease. In contrast to TKIs, interferon (IFN) is directly toxic to CML progenitor cells, and myeloid growth factors such as GM-CSF may enhance IFN's cytotoxicity. ...

Last Updated: 22 Jul 2014

Go To URL
Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia.
 

Author(s): Carlo Gambacorti-Passerini, Jorge E Cortes, Jeff H Lipton, Anna Dmoszynska, Raymond S Wong, Victor Rossiev, Dmitri Pavlov, Karin Gogat Marchant, Ladan Duvillié, Navin Khattry, Hagop M Kantarjian, Tim H Brümmendorf

Journal: Am. J. Hematol.. 2014 Oct;89(10):947-53.

 

Bosutinib, an orally active, Src/Abl tyrosine kinase inhibitor, has demonstrated clinical activity and acceptable tolerability in chronic phase chronic myeloid leukemia (CP CML). This updated analysis of the BELA trial assessed the safety profile and management of toxicities of bosutinib ...

Last Updated: 16 Sep 2014

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Chronic Myeloid Leukemia" returned 128 free, full-text review articles on human participants. First 3 results:

Moving towards patient-centered decision-making in chronic myeloid leukemia: assessment of quality of life and symptom burden.
 

Author(s): Michele Baccarani, Fabio Efficace, Gianantonio Rosti

Journal: Haematologica. 2014 Feb;99(2):205-8.

 

Last Updated: 5 Feb 2014

Go To URL
Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond.
 

Author(s): Wesam Ahmed, Richard A Van Etten

Journal: Hematology Am Soc Hematol Educ Program. 2013 ;2013():189-200.

 

In patients with chronic myeloid leukemia (CML) in chronic phase who have achieved complete molecular remission on imatinib therapy, clinical trials from France and Australia have demonstrated that the majority experience prompt molecular relapse of their leukemia upon discontinuation ...

Last Updated: 9 Dec 2013

Go To URL
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when is this a safe option to consider?
 

Author(s): Kendra Sweet, Vivian Oehler

Journal: Hematology Am Soc Hematol Educ Program. 2013 ;2013():184-8.

 

Mrs G is a 54-year-old woman with a diagnosis of chronic-phase chronic myeloid leukemia dating back 8 years. She had a low-risk Sokal score at diagnosis and was started on imatinib mesylate at 400 mg orally daily within one month of her diagnosis. Her 3-month evaluation revealed a ...

Last Updated: 9 Dec 2013

Go To URL
 
 
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase
 

Status: Recruiting

Condition Summary: Chronic Phase Philadelphia Positive; BCR-ABL Positive; Chronic Myeloid Leukaemia

 

Last Updated: 20 Nov 2014

Go to URL
Pulmonary Vasculopathy Under Second-line Therapy of Chronic Myeloid Leukemia
 

Status: Recruiting

Condition Summary: Chronic Myeloid Leukemia

 

Last Updated: 23 Nov 2014

Go to URL
Front-line Treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) With Dasatinib
 

Status: Recruiting

Condition Summary: Chronic Myeloid Leukemia

 

Last Updated: 10 Dec 2014

Go to URL